Analyst Price Target is $89.11
▲ +46.30% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Keros Therapeutics in the last 3 months. The average price target is $89.11, with a high forecast of $105.00 and a low forecast of $60.00. The average price target represents a 46.30% upside from the last price of $60.91.
Current Consensus is
Buy
The current consensus among 11 contributing investment analysts is to buy stock in Keros Therapeutics. This Buy consensus rating has held steady for over two years.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Read More